Iconovo

Carl Lindgren will soon be starting a new position as Chief Business Development Officer at EQL Pharma and he is active as a board member of the company BioMedica Norden AB. He has previously also worked commercially with inhalation products.

"We are very pleased to welcome Carl Lindgren to Iconovo's Board of Directors. He brings with him more than 30 years of experience in the pharmaceutical industry and has a great knowledge in inhalation products as well as acquisitions and business development", says Gunnar Gårdemyr, Chairman of the Board of Iconovo.

Carl Lindgren joined Iconovo's Board of Directors at the Annual General Meeting on May 22, 2023.

"Iconovo's portfolio of patented inhalers has significant commercial potential in the market for both generic and novel pharmaceuticals. I look forward to contributing to the company's continued development and success in cooperation with the Board and management", says Carl Lindgren.

Om Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) utvecklar nya inhalationsläkemedel i samarbete med in-ternationella läkemedelsföretag. Bolaget tillhandahåller flera typer av patentskyddade inhalatorer som kan generera betydande kommersiella möjligheter vid utveckling av helt nya läkemedel och vid patentutgångar för etablerade läkemedel. Det längst framskridna läkemedelsprojektet är en generisk version av astma- och KOL-läkemedlet Symbicort® som förväntas nå marknaden under 2025. Iconovo planerar att marknadsföra denna produkt i Norden genom sitt dotterföretag Iconovo Pharma, medan bolagets partner Amneal Pharmaceuticals har rättigheterna på de flesta övriga större marknaderna i världen. Certified Adviser är Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm (+46 8 463 80 00, certifiedadviser@penser.se).